Sat.Oct 26, 2024

article thumbnail

Depagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease

HCPLive

The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.

article thumbnail

Microaxial Flow Pump Effects in Infarct-Related Cardiogenic Shock

JAMA Cardiology

This substudy of the Danish-German (DanGer) Shock randomized clinical trial investigates if the use of a microaxial flow pump reduces the need for pharmacological support and what the effects are on hemodynamics and lactate clearance in patients with ST-elevation myocardial infarction–induced cardiogenic shock.

article thumbnail

Standing desks are bad for your health, according to a new study

Medical Xpress - Cardiology

The global market for standing desks is booming, projected to reach US$12.6 billion by 2032 (£9.7 billion). These desks have been hailed as a simple fix for the health risks associated with sitting all day. However, recent research suggests that standing might not be the health booster many hoped for.

Research 105
article thumbnail

Metformin and Congenital Abnormalities; Deprescribing in Patients With Dementia

Med Page Today

(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.

article thumbnail

Kidney Compass: Atacicept for IgAN with Jonathan Barratt, PhD, at Kidney Week 2024

HCPLive

Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.

article thumbnail

Evidence for Mechanical Circulatory Support in Cardiogenic Shock

JAMA Cardiology

In a seminal case series published in 1967, Killip and Kimball reported 81% in-hospital mortality for patients presenting with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). Since then, incremental gains have been made in improving survival with in-hospital mortality, now approximately 40% in a North American health care setting.

article thumbnail

VALIANT: Pegcetacoplan Offers Benefit for UPCR, eGFR, C3 Staining in C3G, IC-MPGN

HCPLive

VALIANT trial data support pegcetacoplan as the first effective therapy for proteinuria, C3c staining, and eGFR stability in C3G and IC-MPGN patients.

75

More Trending

article thumbnail

ORIGIN OLE Data Solidify Atacicept Disease-Modifying Potential for IgA Nephropathy

HCPLive

New ORIGIN trial data show atacicept may slow kidney decline in IgA nephropathy to rates seen with healthy aging, with notable reductions in Gd-IgA1 and UPCR.

69
article thumbnail

End-Organ Injury and Failure: The True DanGer in Cardiogenic Shock

Circulation

Circulation, Ahead of Print.

article thumbnail

New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD

HCPLive

This interview with Bunick highlighted the Level Up phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.

69
article thumbnail

In Which Patients Will PCI Relieve Angina?

Circulation

Circulation, Ahead of Print.

Angina 45
article thumbnail

Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action

HCPLive

In this interview, Bunick spoke about the contents of his Fall Clinical Dermatology presentation specifically regarding mechanisms of action and safety of systemic therapies.

59
article thumbnail

Despite Guidelines, Systemic Corticosteroids Remain Widely Prescribed for Atopic Dermatitis

HCPLive

In these data presented at the Fall Clinical Dermatology conference, population-based data on utilization and duration of systemic corticosteroid exposure was highlighted.

59
article thumbnail

Richard Pratley, MD: FLOW Mortality Data and Allocation Strategies for Semaglutide

HCPLive

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

article thumbnail

Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities

HCPLive

Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.

article thumbnail

Patient-Reported Outcomes for Roflumilast Foam Highlighted for Seborrheic Dermatitis

HCPLive

These findings from the phase 3 STRATUM trial suggest significant DLQI score improvements as early as the second week of treatment with roflumilast foam.

article thumbnail

Carla Nester, MD: Pegcetacoplan in C3 Glomerulopathy and Primary IC-MPGN

HCPLive

Carla Nester, MD, provides perspective on the results of the VALIANT trial and how it informs the role of pegcetacoplan in C3G and IC-MPGN.

52
article thumbnail

Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient

HCPLive

Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.

52